It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. Timeline of Otsuka's History 2014~Present

About OtsukaTimeline of Otsuka's History

  • CorpCorporate
  • PhPharmaceutical business
  • NCNutraceutical business



BeanStalk Kids Center OSAKA opened

Opened as Otsuka Pharmaceutical's first in-house child care center in Tokushima

Otsuka Pharmaceutical was awarded “Diversity Management Selection 100” from the Japan Ministry of Economy, Trade and Industry


Samsca introduced in Japan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Vasopressin V2-receptor antagonist

Strategic alliance with IBM in the Central Nervous System (CNS) field

DELTYBA launched in Europe and Japan

Treatment for multidrug-resistant tuberculosis (MDR-TB)

NUEDEXTA launched in U.S.

Pseudobulbar affect (PBA)


Milical launched in Japan

Milical sold in Japan is imported from France-based Nutrition et Santé

Brazil-based Jasmine joined group

EQUELLE launched

Calorie Mate recognized with Good Design Long Life Design Award 2014



Tatsuo Higuchi appointed president and representative director of Otsuka Pharmaceutical Co. Ltd. in addition to existing role as president, representative director and CEO of Otsuka Holdings


U.S.-based Avanir Pharmaceuticals, Inc. joined group

Abilify Maintena launched

Antipsychotic drug

Otsuka Australia Pharmaceutical Pty Ltd Opens in Australia

Otsuka Pharmaceutical opens its first office in Australia, furthering the company's aim of bringing innovative new treatments to patients in Oceania.

REXULTI launched in the U.S.

Adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia.


U.S.-based FoodState joined group

ORONAMIN C DRINK marks its 50th Anniversary in Japan

ORONAMIN C DRINK began production and sales in South Korea
ORONAMIN C DRINK began sales in Hong Kong

Kenja-no-shokutaku Double Support launched in Hong Kong

Otsuka Pharmaceutical subsidiary Nutrition & Santé (N&S) acquired BIOCENTURY, a leading Spanish health and functional foods company



Donated funds for a Rural Health Center in Myanmar

The facility aims to provide stable maternal and child health services including promotion of midwife-assisted childbirth and health education for local residents.

Otsuka Joins UN Global Compact (UNGC)*

Otsuka Holdings Co., Ltd. became a signatory to the United Nations Global Compact (UNGC) in order to express its commitment to corporate social responsibility (CSR) and sustainability.

  • The Global Compact is an encouragement for companies to pursue sustainable growth and be a good member of society.


RIKEN CDB-Otsuka Pharmaceutical Collaboration Center launched in Kobe, Japan.

ICLUSIG® Tablets 15 mg launched in Japan

Drug for chronic myeloidlLeukemia and Philadelphia postive acute lymphoblastic leukemia

Otsuka signed Japan-exclusive license agreement with Takara Bio

License agreement for the investigational cancer treatment HF10, an Oncolytic Virus

Otsuka Pharmaceutical and Akebia Therapeutics, Inc. entered into a collaboration to develop and commercialize Vadadustat in the U.S.

License agreement for vadadustat, an oral hypoxia-inducible factor (HIF) stabilizer, treatment of anemia associated with chronic kidney disease (CKD).


Otsuka Pharmaceutical forms joint venture company for functional food and beverages in the Philippines

SOYJOY Crispy launched in Japan

Soy bar with the pleasant crunchy texture of puffed soy

POCARI SWEAT and ORONAMIN C DRINK recognized with Good Design Long Life Design Award 2016



Otsuka certified as Health & Productivity Management Outstanding Organization

The Health & Productivity Management Outstanding Organizations Recognition Program was jointly instituted by the Ministry of Economy, Trade and Industry (METI) and Nippon Kenko Kaigi. The program certifies legal entities such as companies that implement quality management practices for ensuring a healthy workforce.

Otsuka receives "Sports Yell Company"Certification* from Japan Sports Agency

  • Certification is granted to corporations that actively implement policies encouraging participation in sports to promote employee health.


Mikeluna® combination ophthalmic solution launched in Japan

Drug for glaucoma and ocular hypertension

Health Canada Approves Otsuka and Lundbeck's REXULTI®

Antipsychotic drug as a treatment for schizophrenia in adults

Otsuka Pharmaceutical acquired Neurovance, Inc., a U.S. privately held, venture-funded, clinical stage pharmaceutical company.

Aiming to widen Otsuka's presence in mental health

Otsuka and Akebia Concludes Licensing Agreement for Akebia's Renal Anemia Drug Vadadustat

Development and marketing territories include Europe, China, etc.

Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)

Otsuka and R-Pharm Announce Licensing Agreement to Commercialize Deltyba (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries

Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba) forMultidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries

Sales commence of Otsuka prescription drugs in Myanmar


Introduced BODYMAINTÉ Brand with the conditioning food BODYMAINTÉ Jelly

BODYMAINTÉ Jelly, a conditioning food to support athletic performance

Otsuka established a new functional food and beverage affiliate"Otsuka Nutraceutical (Thailand) Ltd." in Thailand

Otsuka acquired Daiya, a rapidly growing plant-based food company in North America

EQUELLE launched in US

to contribute to women's health in the US



REXULTI® Tablets launched in Japan

JYNARQUE approved by U.S. FDA as the first treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)

Vasopressin V2-receptor antagonist

Otsuka Pharmaceutical established subsidiary in Singapore

Otsuka acquired Visterra

Visterra's exceptional antibody platform technology joined up with Otsuka

Quick Navi-Reader for diagnosis of influenza to be launched in Japan


Subsidiary of Otsuka, Nutrition & Santé acquired BC BIO, a French manufacturer of organic food products

Kenja-no-Kaimin Sleep Rhythm Support was available throughout Japan

Kenja-no-Kaimin Sleep Rhythm Support, the food with Function Claim from the Consumer Affairs Agency of Japan based on the regulation of sleep-wake rhythms and enhancement of the quality of sleep



Tokushima Mima Factory completed


Selincro® Tablets launched in Japan

Drug to reduce alcohol consumption in alcohol-dependent patients


Otsuka established health beverage subsidiary in Myanmar

Deliciously Illustrated SketchCook wins in three categories at PR Awards Asia 2019

Dietary education app promotes awareness about the importance of meals and nutrition to children

POCARI SWEAT marketing wins top prize at Japan Marketing Awards

The brand has successfully fostered an image of being supportive to young people and continues to expand the market



Makoto Inoue appointed president and representative director of Otsuka Pharmaceutical Co., Ltd.

Otsuka awarded grand prize in Tokyo Metropolitan Government Women's Participation Awards

Otsuka Holdings was selected for "Nadeshiko brand" designation*

  • A listed company that excels in promoting women's careers


Otsuka enters multi-project drug discovery collaboration with PhoreMost Limited

Otsuka established subsidiary in Malaysia


Otsuka established health beverage subsidiary in Mexico